Resmed Inc ((RMD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: ResMed Inc. is conducting a study titled ‘Nyx3 Eye Mask Physiological Data Collection Study’ to evaluate data quality from the Nyx3 eye mask and its effect on sleep onset latency. This study aims to enhance understanding of sleep staging and improve sleep health solutions.
Intervention/Treatment: The study tests the Nyx3 eye mask and Hypnodyne headband, used together to collect physiological data during sleep. The Nyx3 mask features a paced breathing function intended to influence sleep onset.
Study Design: This observational study uses a prospective time perspective. Participants will wear the devices at home for one night, allowing data collection in a natural sleep environment.
Study Timeline: The study was first submitted on June 24, 2025, with the latest update on July 25, 2025. It is not yet recruiting, indicating preparations are underway for participant enrollment.
Market Implications: This study could positively impact ResMed’s stock by showcasing innovation in sleep technology. As sleep health gains attention, advancements like Nyx3 may strengthen ResMed’s market position against competitors.
Closing Sentence: The study is ongoing, with further details available on the ClinicalTrials portal.